Technical Analysis for VBS - Vectus Biosystems Ltd
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.23% | |
| Bollinger Band Squeeze | Range Contraction | -1.23% | |
| Narrow Range Bar | Range Contraction | -1.23% | |
| Inside Day | Range Contraction | -1.23% | |
| Gapped Up | Strength | -1.23% |
| Alert | Time |
|---|---|
| Non-ADX 1,2,3,4 Bearish Retracement Entry | 20 days ago |
| Fell Below Previous Day's Low | 20 days ago |
| Down 1% | 20 days ago |
| Fell Below 10 DMA | 20 days ago |
| Possible Inside Day | 21 days ago |
Get this analysis on your stocks daily!
Vectus Biosystems Ltd Description
Vectus Biosystems Limited is engaged in medical Research and Development. The Company's drug candidates can be orally administered. The Company's primary lead compound, VB0004, has been shown to be both anti-hypertensive and anti-fibrotic in the heart and kidneys. Using its platform technology, the Company has constructed a library of more than 200 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH), as well as pulmonary fibrotic diseases. Accugen is a platform, developed by the Company's subsidiary, Accugen Pty Limited. Accugen comprises reagents and software that quantitate quantitative polymerase chain reaction (qPCR) reactions, which measures the amount of Deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in a sample. It identifies drug targets with specific activity in the heart, kidneys, lungs and liver.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Software Medicine Disease Diseases Pound Heart Platform Technology Medical Research Fibrosis Hepatitis Fibrotic Diseases Polymerase Chain Reaction Steatohepatitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.05 |
| 52 Week Low | 0.076 |
| Average Volume | 127,337 |
| 200-Day Moving Average | 0.353 |
| 50-Day Moving Average | 0.088 |
| 20-Day Moving Average | 0.082 |
| 10-Day Moving Average | 0.080 |
| Average True Range | 0.003 |
| RSI (14) | 40.12 |
| ADX | 25.61 |
| +DI | 32.026 |
| -DI | 46.623 |
| Chandelier Exit (Long, 3 ATRs) | 0.079 |
| Chandelier Exit (Short, 3 ATRs) | 0.086 |
| Upper Bollinger Bands | 0.087 |
| Lower Bollinger Band | 0.076 |
| Percent B (%b) | 0.36 |
| BandWidth | 13.497 |
| MACD Line | -0.004 |
| MACD Signal Line | -0.006 |
| MACD Histogram | 0.0014 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.080 | ||||
| Resistance 3 (R3) | 0.080 | 0.080 | 0.080 | ||
| Resistance 2 (R2) | 0.080 | 0.080 | 0.080 | 0.080 | |
| Resistance 1 (R1) | 0.080 | 0.080 | 0.080 | 0.080 | 0.080 |
| Pivot Point | 0.080 | 0.080 | 0.080 | 0.080 | 0.080 |
| Support 1 (S1) | 0.080 | 0.080 | 0.080 | 0.080 | 0.080 |
| Support 2 (S2) | 0.080 | 0.080 | 0.080 | 0.080 | |
| Support 3 (S3) | 0.080 | 0.080 | 0.080 | ||
| Support 4 (S4) | 0.080 |
